Clinical trial · Observational
A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors
A Real-world Non-interventional Observational Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors (TKIs) in the Patients With Non-small Cell Lung Cancer Complicated With Brain Metastases
NCT03424980CI-TRIAL-00031607unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a real-world non-interventional observational study. The study was designed to evaluate the effectiveness and safety of clinical treatments in the patients with advanced non-small cell lung cancer (NSCLC) complicated with brain metastases in clinical practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tyrosine kinase inhibitors | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Tyrosine kinase inhibitors
- description
- Diagnosed patients with advanced non-small cell lung cancer (NSCLC) with brain metastases who were administered with tyrosine kinase inhibitors only or combination therapies of tyrosine kinase inhibitors
- interventionNames
- Combination Product: Tyrosine kinase inhibitors
Primary outcomes (1)
- measure
- Percentage of patients who are not observed with the event of objective remission
- timeFrame
- 2013 - 2017
- description
- Percentage of patients who are not observed with the event of objective remission
Secondary outcomes (1)
- measure
- Percentage of patients who are not observed with the event of disease progression
- timeFrame
- 2013 - 2017
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * The patients were treated with lung cancer and were enrolled from Jan 2013 to Jun 2017 * The patients with advanced (Clinical stage: Phase IV) non-small cell lung cancer who have complete core health medical records (HMRs); * The patients who are observed with brain metastases diagnosed by imaging methods; * The patients who have complete clinical data for diagnosis time of brain metastases, and overall survival/effectiveness; * The patients who are administered with tyrosine kinase inhibitors only or combination therapies of tyrosine kinase inhibitors; Exclusion Criteria: No exclusion criteria are included in the study given that the study is designed as non-interventional and all the treatments followed real-world clinical practice and experiences of clinical physicians.
References
Publications (0)
Data not yet available
No reference posted for this study.